FOLH1 and prostate carcinoma: This commentary explores the transformative potential of PSMA-targeted therapy in revolutionizing care for patients with prostate cancer, inspired by the MedNews Week Keynote Conference from Dr. Scott T. Tagawa, which was given on 24 May 2023 [5].